Brian Casey

Home
Week in Review: Is the party ending for AI firms? | Photon-counting CT | View our AI webinar
January 14, 2022
Home
Week in Review: 7T proton MR spectroscopy | Ultrasound for dense breasts | Jan. 12 webinar on AI
January 7, 2022
Home
Week in Review: PET + blood test for Alzheimer's | Can AI reduce burnout | POCUS for swallowed coins
December 22, 2021
Digital X-Ray
Micro-X makes RSNA debut with miniaturized x-ray technology
Australian x-ray developer Micro-X made its RSNA debut last month, displaying its carbon nanotube miniaturized x-ray tube technology. The company plans to leverage the design to offer x-ray systems that are lighter and more portable than existing systems.
December 22, 2021
2021 12 21 01 56 8422 Micro X Rsna 2021 400
Economics
Volume rebounds, but so do labor costs for imaging admins
Medical imaging volume continues to grow strongly as radiology recovers from the depths of the COVID-19 pandemic. But rising labor costs are bedeviling radiology administrators, according to survey results for the fourth quarter of 2021 in the Medical Imaging Confidence Index.
December 20, 2021
2021 12 20 19 21 3106 2021 12 22 Mici 2021 Q4 Chart 400
Home
Week in Review: How good is photon-counting CT? | AI gets fooled | Private equity in radiology
December 17, 2021
Home
Week in Review: Concerns about Canadian mammo trials | Liver elastography | AI for wrist fractures
December 10, 2021
Home
Top 10 stories from RSNA 2021
December 7, 2021
Home
RSNA 2021: The best RSNA ever? | The PACSman Awards return | RADCast @ RSNA
December 2, 2021
MRI
New MRI scanners drive Philips products at RSNA 2021
Two new MRI scanners at 3-tesla and 1.5-tesla field strengths are among the new product launches at RSNA 2021 for Philips. The company is also demonstrating a midrange CT scanner and a new interventional suite that combines CT with angiography.
November 30, 2021
2021 11 30 16 08 9693 Philips Rsna 2021 400
Previous Page
Page 7 of 140
Next Page
Top Stories
Pituitary Gland Adobe Art Spiral
MRI
Radiomics models based on pituitary MRI predict GHD
The model can help determine if growth hormone deficiency (GHD) is the cause of children's short stature.
Stroke Skull Xray 400
Interventional
EVT improves outcomes in stroke patients over age 90
Patient Woman Doctor2 400
Practice Management
Most patients confused when trying to read radiology reports
Ai Hand
Nuclear Medicine
LLMs rapidly evolving in nuclear medicine
Join Us!
Sponsor Content
Join Us!
More in Home
CT use in the ED has more than doubled over a decade
By Kate Madden Yee
The finding could be due to the "evolving role of CT in ED care delivery," researchers noted.
September 30, 2025
Emergency Entrance
ASTRO: Proton therapy shows promise in breast cancer treatment
By Amerigo Allegretto
Proton radiation achieves similar health-related quality of life measures compared to photon radiation in breast cancer patients.
September 30, 2025
Img 2757
Israeli radiologist discusses response to Oct. 7 attacks
By Will Morton
Workflow and staffing changes led to a reduction in CT turnaround times from 54 minutes to 27 minutes after the October 7, 2023 attack.
September 30, 2025
Representative injuries in patients from the mass casualty incident of October 7, 2023. (A) Axial CT scan at the pelvic level in a 34-year-old male patient shows multiple shrapnel fragments in the pelvis, resulting in fractures of the pelvic bones and lumbar vertebrae (not visible on this image). (B) Coronal reconstruction of a head CT scan in a 20-year-old male patient shows penetrating trauma to the left eyeball with a retained bullet in the orbital cavity. (C) Radiograph of a fetus delivered by emergency cesarean section from a critically injured mother shows a left pneumothorax and catheter in place. (D) Radiograph in a 25-year-old female patient shows a comminuted fracture in the tibial metaphysis with fragment displacement and multiple bony fragments in the surrounding soft tissues.
ASTRO: Trial suggests postoperative RT in high-risk bladder cancer
By Liz Carey
Moderate doses of radiation therapy (RT) after bladder removal surgery cut rates of new pelvic cancer, according to researchers.
September 30, 2025
Moscone Center Astro
ASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progression
By Will Morton
Two cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.
September 29, 2025
Moscone Center Astro
ASTRO: Contemporary IMRT comparable to proton therapy for throat cancer
By Liz Carey
Phase III U.K. TORPEdO trial investigated proton beam therapy for reducing long-term treatment-related toxicities.
September 29, 2025
Moscone Center Astro
NAPT survey results show promise for proton therapy adoption
By Amerigo Allegretto
Proton therapy continues to experience increased clinical use, but barriers to care continue to limit its potential.
September 29, 2025
Survey Form 400
ASTRO: Low-dose RT effective for treating knee osteoarthritis
By Amerigo Allegretto
Research presented at ASTRO 2025 showed the effectiveness of low-dose radiation therapy for treating knee osteoarthritis.
September 29, 2025
Moscone Center Astro
ASTRO: Genomic test predicts benefit of hormone therapy in prostate cancer
By Will Morton
Patients with a prostate tumor subtype known as luminal B had meaningful benefits from the addition of apalutamide to secondary radiotherapy.
September 29, 2025
Moscone Center Astro
ASTRO: Patient navigation key to mitigating RT treatment disparities
By Kate Madden Yee
"Patients are lost and need to be navigated," said presenter Christina Chapman, MD, of Baylor College of Medicine in Houston.
September 29, 2025
Moscone Center Astro
ASTRO: Radiotherapy offers opportunities beyond cancer treatment
By Kate Madden Yee
Radiotherapy isn't just for cancer treatment, according to talks at ASTRO 2025 in San Francisco.
September 28, 2025
Moscone Center Astro
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Previous Page
Page 7 of 180
Next Page